A new study published in the Journal of the American Medical Association reveals that high doses (100 or 200 micrograms) of LSD, specifically MM120, significantly reduced anxiety and depression symptoms in participants with generalized anxiety disorder (GAD) for up to 12 weeks. Lower doses showed no significant improvement. While the safety and tolerability of the treatment were positive, the study's lack of detail regarding the sensory environment used during treatment raises questions about the contribution of non-drug factors to the positive outcomes. The FDA has granted MM120 'breakthrough therapy' status, accelerating its potential approval as a treatment for GAD and other psychiatric disorders.

Prepared by Olivia Bennett and reviewed by editorial team.